Dana-Farber Cancer Institute, Harvard Medical School
Dr. Mark Awad is an Associate Professor of Medicine at Harvard Medical School, as well as Director of Clinical Research and Director of the Advanced Fellowship Program for the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute. He received his undergraduate degree from Harvard University and his MD and PhD degrees from the Johns Hopkins School of Medicine. After completing his residency and chief residency at the Massachusetts General Hospital, and his medical oncology fellowship at the Dana-Farber Cancer Institute, he joined the Dana-Farber faculty in 2014.
Dr. Awad has published over 100 peer-reviewed manuscripts in journals such as New England Journal of Medicine, Journal of Clinical Oncology, Annals of Oncology, Cancer Cell, among others. His research has been recognized with the 2015 ASCO Young Investigator Award, the 2015 IASLC Young Investigator Award, the 2017 ASCO Career Development Award, the 2018 and 2020 ALK Positive/LUNGevity Transformational Research and Clinical Trial Awards, and the 2022 V Foundation Clinical Scholar Program. He is the recipient of the 2018 Ellen and Stephen Fine Award for Outstanding Teaching in Cancer Medicine and the 2022 A. Clifford Barger Excellence in Mentoring Award.
Dr. Awad's main area of clinical and translational investigation is on cancer immunotherapy, vaccine development, cellular therapies, and targeted therapies. His research group has been working to study the genomic and immunologic predictors of response and resistance to lung cancer therapies in order to develop better immune therapies and targeted treatments for patients with cancer.
Amgen (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant, Grant/Research Support; AstraZeneca (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant, Grant/Research Support; Bristol-Myers Squibb (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant, Grant/Research Support; Eli Lilly Pharmaceuticals (Individual(s) Involved: Self; Clinical Condition: Oncology): Grant/Research Support; Merck & Co., Inc. (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant; Mirati, Novartis, Blueprint, Abbvie, Gritstone, NextCure, EMD Serono (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant; Roche Genentech (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant, Grant/Research Support
Saturday, October 15, 2022
11:10 AM – 12:30 PM
Saturday, October 15, 2022
11:20 AM – 11:35 AM
Saturday, October 15, 2022
12:10 PM – 12:30 PM